SUMMARY OF THE NATIONAL-INSTITUTES-OF-HEALTH WORKSHOP ON PRIMARY HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION

被引:28
作者
NIU, MT
JERMANO, JA
REICHELDERFER, P
SCHNITTMAN, SM
机构
[1] Medical Branch, Clinical Research Program, Division of AIDS, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda
关键词
D O I
10.1089/aid.1993.9.913
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
A Workshop on primary human immunodeficiency virus type 1 (HIV-1) infection sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) and the Office of AIDS Research (OAR) of the National Institutes of Health (NIH) was held February 25-26, 1993 in Bethesda, Maryland. The major goals of this scientific meeting were to bring together researchers and infectious disease specialists who have expertise in primary HIV-1 infection (PHI) to review the pathogenesis of PHI, the treatment experience of PHI in humans and of early retroviral infection in animal models, and to devise theoretical and operational strategies for future clinical trials relating to therapeutic intervention of PHI. The proceedings of this workshop are timely and serve to further the development of innovative strategies for the treatment of HIV-1 infection.
引用
收藏
页码:913 / 924
页数:12
相关论文
共 37 条
[1]   PROGRAMMED CELL-DEATH AND AIDS - FROM HYPOTHESIS TO EXPERIMENT [J].
AMEISEN, JC .
IMMUNOLOGY TODAY, 1992, 13 (10) :388-391
[2]  
AMEISEN JC, 1991, IMMUNOL TODAY, V12, P102
[3]   ZIDOVUDINE (AZT) REDUCES VIRUS TITER, RETARDS IMMUNE DYSFUNCTION, AND PROLONGS SURVIVAL IN THE LP-BM5 MURINE INDUCED IMMUNODEFICIENCY MODEL [J].
BASHAM, T ;
RIOS, CD ;
HOLDENER, T ;
MERIGAN, TC .
JOURNAL OF INFECTIOUS DISEASES, 1990, 161 (05) :1006-1009
[4]   HIV-1 BIOLOGICAL PHENOTYPE AND THE DEVELOPMENT OF ZIDOVUDINE RESISTANCE IN RELATION TO DISEASE PROGRESSION IN ASYMPTOMATIC INDIVIDUALS DURING TREATMENT [J].
BOUCHER, CAB ;
LANGE, JMA ;
MIEDEMA, FF ;
WEVERLING, GJ ;
KOOT, M ;
MULDER, JW ;
GOUDSMIT, J ;
KELLAM, P ;
LARDER, BA ;
TERSMETTE, M .
AIDS, 1992, 6 (11) :1259-1264
[5]  
COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6
[6]  
DURAND E, 1991, NEW ENGL J MED, V324, P1062
[7]   HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ACTIVATES THE CLASSICAL PATHWAY OF COMPLEMENT BY DIRECT C1-BINDING THROUGH SPECIFIC SITES IN THE TRANSMEMBRANE GLYCOPROTEIN-GP41 [J].
EBENBICHLER, CF ;
THIELENS, NM ;
VORNHAGEN, R ;
MARSCHANG, P ;
ARLAUD, GJ ;
DIERICH, MP .
JOURNAL OF EXPERIMENTAL MEDICINE, 1991, 174 (06) :1417-1424
[8]   MASSIVE COVERT INFECTION OF HELPER T-LYMPHOCYTES AND MACROPHAGES BY HIV DURING THE INCUBATION PERIOD OF AIDS [J].
EMBRETSON, J ;
ZUPANCIC, M ;
RIBAS, JL ;
BURKE, A ;
RACZ, P ;
TENNERRACZ, K ;
HAASE, AT .
NATURE, 1993, 362 (6418) :359-362
[9]  
FAZELY F, 1991, J ACQ IMMUN DEF SYND, V4, P1093
[10]   PHENOTYPE-ASSOCIATED SEQUENCE VARIATION IN THE 3RD VARIABLE DOMAIN OF THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 GP120 MOLECULE [J].
FOUCHIER, RAM ;
GROENINK, M ;
KOOTSTRA, NA ;
TERSMETTE, M ;
HUISMAN, HG ;
MIEDEMA, F ;
SCHUITEMAKER, H .
JOURNAL OF VIROLOGY, 1992, 66 (05) :3183-3187